Current treatment options for perinatal depression

Area of Science:

• Obstetrics and Gynecology
• Psychiatry
• Maternal-Fetal Medicine

Background:

• Perinatal depression (PND) affects a significant portion of patients, contributing to maternal mortality.
• Despite its prevalence, PND remains underdiagnosed and undertreated, highlighting a critical gap in maternal healthcare.
• This review synthesizes current knowledge on PND screening, treatment, and novel therapeutic approaches.

Purpose of the Study:

• To provide an updated, clinically relevant review of perinatal depression.
• To synthesize current evidence on screening methods, established treatments, and emerging therapies for PND.
• To inform clinical practice regarding the diagnosis and management of PND.

Main Methods:

• Systematic review of current literature and clinical guidelines.
• Analysis of recent findings on pharmacological and non-pharmacological treatments for PND.
• Evaluation of emerging technologies and interventional psychiatry for PND management.

Main Results:

• Universal screening for PND using validated tools is recommended.
• Selective serotonin reuptuptake inhibitors are first-line treatments, with demonstrated safety during pregnancy and lactation.
• Emerging treatments include the neurosteroid zuranolone for rapid postpartum depression relief, and interventional psychiatry options like ketamine and TMS for select patients.
• Digital tools and AI show potential for early detection and personalized interventions, pending further validation.

Conclusions:

• Individualized, evidence-based treatment is essential for optimizing maternal and neonatal outcomes in PND.
• A combination of pharmacologic and non-pharmacologic interventions can significantly improve outcomes for both parent and child.
• New therapeutic agents and digital innovations hold promise for PND care but necessitate careful clinical integration.